Data Set Finalization Section
A Data Set Finalization section defines the transition from actively managed trial data to a controlled analysis-ready data set. It documents readiness criteria and responsibilities without duplicating the statistical methods themselves.
A Data Set Finalization section states the checks, reconciliations, approvals, and locking/finalization steps required before an analysis-ready trial data set is released.
Key details
Important caveats
Scope Boundary
Keep finalization separate from Data Analysis methods. Terminology such as database lock, freeze, or final data set can vary by trial system and workflow.
Further guidance
Content
Describe prerequisite review and reconciliation, unresolved-issue criteria, correction completion, responsible approvals, finalization or lock process, controlled extraction/release, and handling of any post-finalization change.
Purpose
Create an auditable decision point showing when the data are sufficiently complete and controlled for planned analysis.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities